Labiana Health

Labiana Health Financing Cash Flow

The Net Financing Cash Flow of Labiana Health (LAB.MC) as of Nov 19, 2026 is -2.50 M EUR. In the previous year, Net Financing Cash Flow was 17.51 M EUR — a change of -114.25% (lower).

Financing Cash Flow

-2.50 MEUR

YoY

-114.25%

Last updated:

Net Financing Cash Flow of Labiana Health is 2022 -2.50 M EUR. Net Financing Cash Flow of Labiana Health was 2021 17.51 M EUR. It decreases by -114.25% lower compared to the previous year.

The Labiana Health Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
3.77 M EUR
Jan 1, 2019
17.51 M EUR
Jan 1, 2022
-2.50 M EUR
The Labiana Health Financing Cash Flow history
YEARFinancing Cash FlowYoY
-2.50 MEUR-114.25%
17.51 MEUR+364.10%
3.77 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Net Financing Cash Flow of Labiana Health is -2.50 M EUR in 2022.

Net Financing Cash Flow of Labiana Health changed from 17.51 M EUR to -2.50 M EUR, representing a -114.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Labiana Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Labiana Health

All Key Metrics — Labiana Health